Business Wire

Alter Domus Strengthens its Competitive Differentiation with Continued Investments in European Operational Excellence

25.11.2021 10:00:00 EET | Business Wire | Press release

Share

Alter Domus, a leading provider of integrated solutions for the alternative investment industry, is enhancing its European service offering by making substantial investments in its central operations.

The initiative is focused on building additional technology capability, expanding its European footprint, and continuing to recruit exceptional, multilingual talent to support Alter Domus in providing corporate and fund services to investors and managers in private equity, real assets, and debt capital markets.

Launching an Ambitious Digital Agenda

At the core of its €50 million investment is technology. Alter Domus is pursuing an ambitious digital agenda in software development, network and infrastructure, security and systems engineering, and quality assurance.

This complements the rollout of new client-facing technology, CorPro, digitalising investors’ and managers’ traditional workflows to significantly improve access to data and achieve efficiencies across different geographies, funds, and product types.

This in-house technology was enhanced with the acquisition of London-based SaaS platform, Credit-Vision, whose solution for corporate credit investors was vertically integrated into Alter Domus’ technology stack during 2021.

Scaling via European footprint

In addition to expanding its Irish operations in 2021, Alter Domus opened its doors in Lithuania and now benefits from operations centres in Cork, Vilnius, and Malta to house central operations as well as functions including technology and HR. In Ireland and Lithuania alone, Alter Domus has hired more than 200 new employees in 2021. Luxembourg continues to play a critical role in knowledge sharing to Alter Domus’ new operations centres as it remains a leading European centre of excellence.

Exceptional, Specialised Talent

Across Europe, Alter Domus plans to hire an additional 270 technology, accounting, legal, compliance and tax specialists in Luxembourg, Cork, and Vilnius in 2022, to scale across the continent.

This will support Alter Domus in capturing the growing demand for incremental outsourcing as global alternatives investment managers in North America and Asia – who have an estimated $2.5 trillioni in dry powder to deploy – increasingly look to Europe to launch and manage new funds.

Alter Domus has fully deployed a hybrid working model and benefited from a greater appetite amongst exceptional talent to switch functional roles since the beginning of the pandemic. Those alternatives specialists seeking to switch are demanding a more technology-centric role without losing their sector expertise.

Through a proprietary training program, The acADemy, Alter Domus employees are enhancing their technical, professional and leadership skills. 1,800 Alter Domus employees in 13 European locations have already benefited from The acADemy, amounting to over 30,000 hours of training delivery.

Sandra Legrand, Regional Executive for Europe at Alter Domus, said: “In a year when Alter Domus has topped $1 trillion in assets under administration, we have in place the strongest technological capabilities and expanded our talented central operations team to support our clients and the rising complexity of their assets.”

“Our technology investment programme is strengthening our ability to help alternatives investors and managers grapple with a data deluge. Our technology is optimising managers fund and portfolio performance when they’re raising, managing, and deploying funds, and reporting this all back to their end-investors to overcome the intricate web of regulatory and compliance requirements.”

Heather Crowley- Kerr, Head of Central Operations Europe at Alter Domus, said: “Fund administration is a people industry increasingly defined by digital transformation. Whilst we’re automating our processes to serve our clients more efficiently, we’ve more than doubled our workforce in central operations since 2016 to maintain our hybrid operating model which blends human with digital.”

“Through an internal knowledge transfer system, we’ve exported some deep technical knowledge and experience that sits within Luxembourg and Malta to two additional hubs in Cork and Vilnius which now employ over 350 people. In the last year, we’re proud to have trained over 175 employees in the entire alternatives product lifecycle, so we retain our competitive advantage in being the only fund services and asset administration provider solely dedicated to providing superior expertise to private equity, credit, real estate and infrastructure investors and managers.

We look forward to our continued growth within our central operations and to welcoming additional talent to join us on the Alter Domus journey.”

# #

ABOUT ALTER DOMUS

Alter Domus is a leading provider of fund administration, debt capital markets and corporate services for the alternative investment industry. Through vertical integration, dedicated teams provide support and bespoke solutions across entire value chains. By tapping into a talent pool of more than 3,300 employees across 36 offices in 21 jurisdictions, our expertise and cutting-edge technology combine to put clients ahead of the game.

With an established professional focus on private equity, venture capital, real estate, infrastructure, and credit sectors, we offer fund administration, debt capital markets services, corporate services, depositary services, capital administration, transfer pricing, domiciliation and management company services. Our specific experience in the debt capital markets sector allows us to provide specialist solutions such as loan administration, agency services, trade settlement and CLO manager services.

Alter Domus proudly serves 16 of the 20 largest private equity houses, 17 of the 20 largest real estate firms, and 17 of the 20 largest private debt managers in the world. For more information, please visit: www.alterDomus.com.


i Source: Preqin (as at November 2021) North America = $1.778 Tn and APAC = $0.762 Tn of dry powder

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Contact:
Patrick Gritti
Global Head of Marketing and Communications, Alter Domus
+352 48 18 28 3835
+352 661 112 515
patrick.gritti@alterdomus.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release

International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye